Bioventus lowered 2026 revenue guidance to $590 million to $595 million, primarily due to weaker BGS expectations, while reaffirming adjusted EPS guidance of $0.75 to $0.79 and adjusted operating cash flow guidance of $84 million to $89 million.
BVS · Bioventus Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Bioventus reported nine-month net sales of 427,739 and Adjusted EBITDA of 87,534, in thousands, for the period ended September 26, 2026; sales increased 4.3%. Discretionary term-loan prepayments totaled $57.0 million, and interest expense decreased $9.0 million.
Bioventus reported third-quarter revenue of $142.4 million, up 3%, with GAAP diluted EPS of $0.08 versus $0.05 a year earlier, and continues to review potential strategic alternatives.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Bioventus reported Q2 revenue of $153.2 million (up 4%) driven by double-digit Pain Treatments growth, reaffirmed full-year 2026 guidance, made a $20 million discretionary debt prepayment, and initiated a review of strategic alternatives following an unsolicited acquisition proposal.
- + Made a $20.0 million discretionary principal prepayment on term loan, with debt pay down of $46 million YTD and leverage below 2x
- + Board initiated review of strategic alternatives following unsolicited acquisition proposal and multiple expressions of interest
- + PRP and PNS businesses showed accelerated capital placements, new customer wins, and positive market feedback
- − Company took proactive channel actions in BGS during Q2 that had a temporary impact on the business
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 35.3M | Q2 2026 | — |
| International Segment Adjusted EBITDA non-GAAP | $4.78M | Three Months Ended June 27, 2026 filing | — |
| U.S. Segment Adjusted EBITDA non-GAAP | $30.49M | Three Months Ended June 27, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BVS
this stock
Bioventus Inc.
|
$894.85M | +42.7% | -0.9% | 13.3 | 3.6% |
|
ABT
Abbott Laboratories
|
$180.95B | -16.6% | +5.7% | 39.0 | 1.1% |
|
MDT
Medtronic plc
|
$128.83B | +4.9% | +8.4% | 24.8 | 1.8% |
|
SYK
Stryker Corp
|
$121.12B | -9.5% | +11.2% | 33.9 | 1.7% |
|
BSX
Boston Scientific Corp
|
$63.26B | -54.2% | +12.5% | 18.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 2, 2026
- This year
- 14
Bioventus reported nine-month net sales of 427,739 and Adjusted EBITDA of 87,534, in thousands, for the period ended September 26, 2026; sales increased 4.3%. Discretionary term-loan prepayments totaled $57.0 million, and interest expense decreased $9.0 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BVS | -3.4% | -25.4% | +24.8% | -20.3% | +42.7% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +0.5% | -19.9% | +28.3% | -16.9% | +35.7% |